Baird Reiterates an 'Outperform' on Alexion Pharmaceuticals (ALXN); Enobia Investment Starts Bearing Fruit

Baird reiterates an 'Outperform' on Alexion Pharmaceuticals (NASDAQ: ALXN) price target of $100.00.

Analyst, Christopher J. Raymond, said, "Remain positively inclined on ALXN's Enobia acquisition after initial Phase II asfotase alfa data in adults showed positive efficacy and safety. While the abstract has been out there for some time, we still see today's presentation at a major medical conference as further validation of the drug's mechanism. With our confidence in a 2014 pediatric filing now bolstered, and sizable option value in adults, we continue to like this acquisition."

For an analyst ratings summary and ratings history on Alexion Pharmaceuticals click here. For more ratings news on Alexion Pharmaceuticals click here.

Shares of Alexion Pharmaceuticals closed at $90.22 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Cantor Fitzgerald Reiterates Overweight Rating on Merlin Labs (MRLN)
• UBS Reiterates Buy Rating on Hilton Worldwide (HLT)